We are thrilled to announce that HuntX Pharma has been awarded Ipsen’s Golden Ticket 2024, at BioLabs France cutting-edge Hôtel-Dieu de France facility. HuntX Pharma is pioneering a novel therapeutic approach for Huntington's disease, with promising potential applications for other neurological conditions. Congratulations to their exceptional team - we are delighted to support their journey.
À propos
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com.
- Site web
-
http://www.ipsen.com
Lien externe pour Ipsen
- Secteur
- Fabrication de produits pharmaceutiques
- Taille de l’entreprise
- 5 001-10 000 employés
- Siège social
- Boulogne Billancourt
- Type
- Société cotée en bourse
- Domaines
- Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins et Primary Care
Lieux
Employés chez Ipsen
Nouvelles
-
🌍✨ Ipsen made a significant impact at the ESG Life Sciences Summit Europe 2024! 🌍✨ Gareth Collins, VP of Sustainability & EHS, presented our approach to CSRD compliance, emphasizing the integration of sustainability into our business transformation strategy, and showcased Generation Ipsen, our sustainability strategy. Learn more: https://lnkd.in/ecRkSXmN #ESG #Sustainability #LifeSciences #CSRD #GenerationIpsen
-
The right science at the right time. We are excited to explore the potential of Ipsen’s two ADCs, harnessing the power of novel targets and payloads to unlock their potential as we strive to bring new treatments to people living with hard to treat forms of cancer with few or no options. Read about Ipsen’s Early Development strategy here: https://lnkd.in/d-_y7zFi
-
Early research and development expansion continues at Ipsen Early research and development remains a priority as we continue to build a high-value, sustainable pipeline, at every stage of development. We sat down with Ipsen SVP Mary Jane Hinrichs to discuss data-driven decisions and their influence on early development success. Read more here: https://lnkd.in/d-_y7zFi
-
Ipsen announces global licensing agreement with Foreseen Biotechnology, adding second pre-clinical ADC to its portfolio. Learn more: https://lnkd.in/d-hbdhSA
-
Our strategy has helped us add more than 25 new programs to our pipeline and achieve consecutive years of sustainable growth since 2020. 📈 We focus on: 🤝 Innovation 📋Pipeline 🍃Sustainable Growth Read our 2023 Annual Report to learn how collaboration combined with our strategy is making our growth possible.
-
Ipsen expands collaboration and license agreement for development of therapy in advanced pancreatic and extra-pancreatic neuroendocrine tumors. Learn more: ipsen.to/XQLYmxg
-
🎉🌈 Celebrating Spectra ERG's First Anniversary! 🌈🎉 One year ago, Eric, Sam, Courtney, and Aline came together to launch Spectra ERG at Ipsen, dedicated to supporting our LGBTQIA+ community. Spectra is a beacon of advocacy, education, and community outreach with a clear mission: to empower colleagues, highlight LGBTQIA+ experiences, and create an inclusive workplace. Find out more here about Spectra’s focus on the future here https://ipsen.to/A0A4w9 #Inclusion #Diversity #LGBTQIA #SpectraERG #Pride #Ipsen #GenerationIpsen
Spectra ERG Celebrates its First Anniversary Supporting the LGBTQIA+ Community at Ipsen - Global
https://www.ipsen.com
-
For those living with the rare cholestatic liver disease #PrimaryBiliaryCholangitis (PBC), symptoms are chronic, often unbearable and have a significant negative impact on quality of life. For many, including Sabrina, debilitating fatigue and pruritus (intolerable itching) affect life every day. Watch Sabrina’s full story here: [link to Ipsen.com]
Pages similaires
Parcourir les offres d’emploi
Financement
Dernier round
Capital après introduction en Bourse29 134 597,00 $US